Connection

Patrick O'Neil to Middle Aged

Back to Details
This is a "connection" page, showing publications Patrick O'Neil has written about Middle Aged.
Patrick O'Neil
Connection Strength
0.694
Middle Aged
  1. Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes. Int J Obes (Lond). 2020 05; 44(5):990-998.
    View in: PubMed
    Score: 0.049
  2. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018 08 25; 392(10148):637-649.
    View in: PubMed
    Score: 0.045
  3. Characteristics of Weight Loss Trajectories in a Comprehensive Lifestyle Intervention. Obesity (Silver Spring). 2017 12; 25(12):2062-2067.
    View in: PubMed
    Score: 0.042
  4. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 11; 19(11):1529-1536.
    View in: PubMed
    Score: 0.042
  5. Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial. J Diabetes Complications. 2017 May; 31(5):891-897.
    View in: PubMed
    Score: 0.040
  6. Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. Obesity (Silver Spring). 2016 11; 24(11):2269-2277.
    View in: PubMed
    Score: 0.040
  7. Effects on cardiovascular risk factors of weight losses limited to 5-10. Transl Behav Med. 2016 09; 6(3):339-46.
    View in: PubMed
    Score: 0.039
  8. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. Endocr Pract. 2016 11; 22(11):1277-1287.
    View in: PubMed
    Score: 0.039
  9. Changes in cardiovascular risk factors with participation in a 12-week weight loss trial using a commercial format. Eat Behav. 2014 Jan; 15(1):68-71.
    View in: PubMed
    Score: 0.032
  10. Relations of hedonic hunger and behavioral change to weight loss among adults in a behavioral weight loss program utilizing meal-replacement products. Behav Modif. 2013 Nov; 37(6):790-805.
    View in: PubMed
    Score: 0.032
  11. Changes in weight control behaviors and hedonic hunger during a 12-week commercial weight loss program. Eat Behav. 2012 Dec; 13(4):354-60.
    View in: PubMed
    Score: 0.029
  12. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012 Jul; 20(7):1426-36.
    View in: PubMed
    Score: 0.029
  13. Remission of metabolic syndrome following a 15-week low-calorie lifestyle change program for weight loss. Int J Obes (Lond). 2009 Jan; 33(1):144-50.
    View in: PubMed
    Score: 0.023
  14. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002 Jul; 10(7):633-41.
    View in: PubMed
    Score: 0.015
  15. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 01 11; 327(2):138-150.
    View in: PubMed
    Score: 0.014
  16. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
    View in: PubMed
    Score: 0.013
  17. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med. 2019 08 08; 381(6):520-530.
    View in: PubMed
    Score: 0.012
  18. The body mass index-mortality relationship in white and African American women. Obes Res. 1998 Jul; 6(4):268-77.
    View in: PubMed
    Score: 0.011
  19. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care. 2018 08; 41(8):1590-1599.
    View in: PubMed
    Score: 0.011
  20. Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study. Obesity (Silver Spring). 2018 01; 26(1):61-69.
    View in: PubMed
    Score: 0.011
  21. The National Women's Study: relationship of victimization and posttraumatic stress disorder to bulimia nervosa. Int J Eat Disord. 1997 Apr; 21(3):213-28.
    View in: PubMed
    Score: 0.010
  22. Effects of body fat distribution on body size estimation accuracy among obese women. Int J Obes Relat Metab Disord. 1997 Mar; 21(3):250-3.
    View in: PubMed
    Score: 0.010
  23. Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016 11; 24(11):2278-2288.
    View in: PubMed
    Score: 0.010
  24. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes (Lond). 2016 09; 40(9):1369-75.
    View in: PubMed
    Score: 0.010
  25. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring). 2014 Oct; 22(10):2137-46.
    View in: PubMed
    Score: 0.008
  26. Executive control circuitry differentiates degree of success in weight loss following gastric-bypass surgery. Obesity (Silver Spring). 2013 Nov; 21(11):2189-2196.
    View in: PubMed
    Score: 0.008
  27. The Food Craving Questionnaire-Trait in a bariatric surgery seeking population and ability to predict post-surgery weight loss at six months. Eat Behav. 2012 Dec; 13(4):366-70.
    View in: PubMed
    Score: 0.007
  28. Prefrontal cortex transcranial direct current stimulation (tDCS) temporarily reduces food cravings and increases the self-reported ability to resist food in adults with frequent food craving. Appetite. 2011 Jun; 56(3):741-6.
    View in: PubMed
    Score: 0.007
  29. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan; 19(1):110-20.
    View in: PubMed
    Score: 0.006
  30. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring). 2007 Apr; 15(4):895-905.
    View in: PubMed
    Score: 0.005
  31. Vagus nerve stimulation acutely alters food craving in adults with depression. Appetite. 2007 Mar; 48(2):145-53.
    View in: PubMed
    Score: 0.005
  32. Changes in food cravings during low-calorie and very-low-calorie diets. Obesity (Silver Spring). 2006 Jan; 14(1):115-21.
    View in: PubMed
    Score: 0.005
  33. Findings and outcomes of psychological evaluations of gastric bypass applicants. Surg Obes Relat Dis. 2005 Nov-Dec; 1(6):523-7; discussion 528-9.
    View in: PubMed
    Score: 0.005
  34. Night eating syndrome: effects of brief relaxation training on stress, mood, hunger, and eating patterns. Int J Obes Relat Metab Disord. 2003 Aug; 27(8):970-8.
    View in: PubMed
    Score: 0.004
  35. Restraint and age at onset of obesity. Addict Behav. 1981; 6(2):135-8.
    View in: PubMed
    Score: 0.003
  36. A prospective study of holiday weight gain. N Engl J Med. 2000 Mar 23; 342(12):861-7.
    View in: PubMed
    Score: 0.003
  37. Psychosocial aspects of total parenteral nutrition. Psychosomatics. 1980 Feb; 21(2):115-25.
    View in: PubMed
    Score: 0.003
  38. Short-term impact of a church-based approach to lifestyle change on cardiovascular risk in African Americans. Ethn Dis. 2000; 10(1):17-23.
    View in: PubMed
    Score: 0.003
  39. Cognitive appraisals of dietary transgressions by obese women: associations with self-reported eating behavior, depression, and actual weight loss. Int J Obes Relat Metab Disord. 1999 Mar; 23(3):231-7.
    View in: PubMed
    Score: 0.003
  40. Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 1997 Dec; 67(3):272-6.
    View in: PubMed
    Score: 0.003
  41. Prevalence of binge eating disorder in obese adults seeking weight loss treatment. Eat Weight Disord. 1997 Sep; 2(3):117-24.
    View in: PubMed
    Score: 0.003
  42. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull. 1993; 29(2):183-8.
    View in: PubMed
    Score: 0.002
  43. Naltrexone and dysphoria: a double-blind placebo controlled trial. Biol Psychiatry. 1987 Jun; 22(6):710-6.
    View in: PubMed
    Score: 0.001
  44. A controlled trial of naltrexone in obese humans. Int J Obes. 1985; 9(5):347-53.
    View in: PubMed
    Score: 0.001
  45. Experienced control and participation in treatment of obesity. Psychol Rep. 1980 Dec; 47(3 Pt 2):1127-34.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.